Two different goals inside the same joint

Both ChondroFiller and hyaluronic acid (HA) are injected into the hip joint as outpatient, ultrasound-guided treatments — but that is where the similarity ends. They pursue entirely different goals, and choosing between them depends on what is actually wrong with the hip, not on personal preference.

ChondroFiller is an acellular collagen scaffold. Injected into a focal area of cartilage damage, it provides a temporary structure that supports the body's own repair processes by allowing progenitor cells to migrate into the defect. The aim is to promote endogenous repair of the damaged tissue — it is not a lubricant, and it is not designed to simply mask pain.

HA viscosupplementation works in a different way altogether. The hip joint normally contains synovial fluid rich in naturally occurring hyaluronic acid, which keeps the joint well-lubricated and cushioned. In osteoarthritis that fluid becomes thinner and less effective. An HA injection restores some of that viscosity and lubricity, easing discomfort and improving movement — but it does not repair or regenerate the cartilage surface itself.

Which approach is appropriate for a given patient turns on the type and stage of hip disease. A focal cartilage defect in an otherwise well-preserved hip points in one direction; diffuse symptomatic wear across the joint points in another. It is worth noting that no published head-to-head trial has directly compared the two treatments specifically in the hip, so clinical decisions draw on separate — and quite different — bodies of evidence.

Which hip conditions suit which treatment

The starting point for any treatment decision is the type of hip problem — specifically whether the damage is focal or diffuse, and how far the joint has deteriorated overall.

ChondroFiller tends to suit patients with a discrete, contained area of cartilage damage on the acetabulum (the socket side of the hip joint). This pattern is most commonly associated with femoroacetabular impingement (FAI) — a condition where subtle differences in hip shape cause repeated friction, wearing away a localised patch of cartilage in an otherwise reasonably healthy joint. Published evidence supports its use in defects larger than 2 cm² where surrounding cartilage is still intact. It is not appropriate for hips where osteoarthritis has spread broadly across the joint surface: in that setting — corresponding to Tönnis grade 2 or 3 on clinical staging — the hip cohort data show poor outcomes.

HA viscosupplementation is generally considered for mild-to-moderate diffuse hip osteoarthritis, where the priority is managing symptoms rather than repairing a specific lesion. It is worth knowing that NICE does not routinely recommend HA injections for hip osteoarthritis, citing limited conclusive evidence — so within NHS pathways it is not standard, though it remains an option privately.

Patients whose hip shows early generalised wear without a distinct focal defect are unlikely to be well-suited to ChondroFiller; other biologic or symptom-management approaches may be more appropriate in that case.

Because staging hip cartilage damage precisely requires MRI and clinical assessment, treatment suitability cannot be established from symptoms alone — a consultant review is needed to determine which pathway fits.

How the two mechanisms differ

Once inside the hip joint, the two treatments behave in fundamentally different ways — and understanding those differences helps make sense of why each suits a different patient profile.

ChondroFiller is a cell-free Type I collagen hydrogel that self-gels within approximately three to five minutes of injection, filling the focal defect with a temporary matrix. The scaffold then works through a process called acellular matrix-induced chondrogenesis — in plain terms, it recruits the patient's own progenitor cells from the surrounding tissue into the defect, providing the structure those cells need to lay down new repair tissue. Ex vivo studies have recorded a 2.4-fold rise in scaffold DNA content within 14 days, confirming that endogenous cell migration does occur. As host tissue establishes, the collagen matrix resorbs naturally; the clinical goal is durable repair tissue that becomes part of the joint, not a permanent implant remaining inside it. This repair process depends on the joint retaining sufficient biological capacity to respond — which is why advanced, generalised osteoarthritis, where that capacity is substantially reduced, represents a contraindication to ChondroFiller.

Hyaluronic acid works by a different route entirely. Injected into the joint space, it restores the viscoelastic properties of synovial fluid — improving lubrication, cushioning cyclic loads, and reducing inflammatory mediators within the fluid. The benefit is palliative: no structural change occurs to the cartilage surface, and symptom relief typically diminishes as the injected HA is metabolised over weeks to months. That is a legitimate clinical role — managing discomfort in a hip where the window for repair-based treatment may have passed — but it is distinct from regeneration.

What the hip-specific evidence shows

Taken together, both treatments have a published evidence base for the hip — but neither has a large, high-quality randomised controlled trial to draw on, and that shared limitation shapes what can reasonably be expected from either.

For ChondroFiller, the foundational hip study is the prospective cohort already introduced: 26 patients, all with FAI and acetabular lesions exceeding 2 cm². What that cohort adds beyond the headline result is context about failure. The minority who fared poorly were precisely those with pre-existing Tönnis grade 2–3 osteoarthritis — reinforcing that the scaffold depends on a biologically capable joint to respond. MRI confirmed cartilage maturation in the successful cases, providing structural rather than purely symptomatic evidence of repair. Modified Harris Hip Score improvements of approximately 30 points have been reported in hip-specific series, offering a functional dimension alongside imaging findings. No large hip RCT exists, however, and the evidence base remains anchored to a single modest cohort supplemented by knee data.

For HA, the volume of evidence is considerably larger but the conclusions are more equivocal. A 2023 systematic review covering 40 studies and 3,350 hip OA patients found only weak evidence of benefit versus baseline, with very high heterogeneity between studies. A 2024 meta-analysis of four RCTs of high-molecular-weight HA in hip OA found no statistically significant advantage over saline for either VAS pain relief (SMD −0.056, p=0.709) or the Lequesne functional index (SMD −0.114, p=0.585). A 24-month retrospective cohort of 101 patients did record a 1.2 VAS-point pain reduction and a 20.76% fall in analgesic use — modest but real symptomatic gains, with no structural change implied.

No head-to-head study comparing ChondroFiller directly with HA in the hip joint has been published, which means the comparison rests on separate evidence streams rather than shared trial data.

The injection itself: what to expect

Practically speaking, both treatments are delivered in an outpatient clinic setting under ultrasound guidance — no theatre admission, no general anaesthetic, and no surgical incision for either.

Image guidance matters because the hip joint target sits between 3.5 and 7 cm below the skin surface, and anatomically important structures — including the femoral nerve and circumflex vessels — run close to the needle path. Real-time ultrasound achieves 90–96% accuracy for hip joint entry, compared with 70–80% for a blind landmark approach; for both ChondroFiller and HA, image-guided placement is the standard at Lincolnshire Hip.

ChondroFiller is delivered in a single outpatient session. Once injected, the collagen scaffold sets in situ inside the focal defect. Because early mechanical loading before the scaffold has stabilised may limit its protective effect on the surrounding cartilage, patients are typically advised to keep loading gentle for a short period after the appointment — a precaution while the matrix settles, not a prolonged restriction. The exact duration is agreed with the treating clinician at the time of the appointment.

HA does not carry the same biomechanical stabilisation concern. Most patients resume normal weight-bearing within a day or two, though mild local tenderness at the hip is common for a short time after the injection. Depending on the product and the clinical response, a course may involve one to three injections spaced several weeks apart.

Deciding which treatment fits your hip

The decision hinges on two variables: where the hip damage is concentrated, and what the treatment is trying to achieve.

A focal cartilage lesion on the acetabulum — in a hip that is otherwise structurally sound — is the profile suited to a regenerative scaffold approach. Diffuse mild-to-moderate OA, where the aim is symptom control rather than structural repair, points toward a palliative option; NICE's current guidance, covered in earlier sections, limits HA's role in that setting. Where wear is more generalised but hip replacement is not yet the right step, Arthrosamid — a permanent polyacrylamide hydrogel working through an entirely different mechanism — represents a third, named alternative that should not be conflated with either ChondroFiller or HA.

Advanced joint deterioration sits outside the indicated range for any of these injections; at that stage the appropriate discussion moves to hip replacement or other surgical options.

Identifying which profile applies to a particular hip requires MRI and a consultant assessment. Imaging determines defect geometry, cartilage integrity, and OA grade — the deciding factors that no amount of background reading can substitute for. A brief online suitability guide on the Lincolnshire Hip site helps patients prepare the right questions before that appointment. Lincolnshire Hip is part of the MSK Doctors group and accepts patients without GP referral for hip assessment, with clinics at Sleaford and Grantham serving patients across Lincolnshire and the wider non-London catchment.

1. [1] Development of an Ex Vivo Osteochondral Biomimetic Platform for Mechanistic Investigation of Cartilage Regeneration. (2025). https://doi.org/10.3390/ijms262311759 https://doi.org/10.3390/ijms262311759
2. [2] Modification of cardiovascular risk factors after viscosupplementation with hyaluronic acid in patients with symptomatic hip and knee osteoarthritis. (2025). https://doi.org/10.55563/clinexprheumatol/tsa1u8 https://doi.org/10.55563/clinexprheumatol/tsa1u8
3. [3] Influence of cartilage defects and a collagen gel on integrity of corresponding intact cartilage: a biomechanical in-vitro study. (2024). https://doi.org/10.1007/s00402-024-05530-z https://doi.org/10.1007/s00402-024-05530-z
4. [4] Arthroscopic utilization of ChondroFiller gel for the treatment of hip articular cartilage defects: a cohort study with 12- to 60-month follow-up. (2021). https://doi.org/10.1093/jhps/hnab002 https://doi.org/10.1093/jhps/hnab002